HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $9 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Arthur He reiterates a Buy rating on LAVA Therapeutics (NASDAQ:LVTX) and maintains a $9 price target.
June 12, 2023 | 10:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Arthur He reiterates a Buy rating on LAVA Therapeutics and maintains a $9 price target.
The Buy rating and maintained $9 price target by HC Wainwright & Co. analyst Arthur He indicates a positive outlook for LAVA Therapeutics. This news is likely to have a positive impact on LVTX's stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100